an overview on leishmania vaccines: a narrative review article

leishmaniasis is one of the major health problems and categorized as a class i disease (emerging and uncontrolled) by world health organization (who), causing highly significant morbidity and mortality. indeed, more than 350 million individuals are at risk of leishmania infection, and about 1.6 million new cases occur causing more than 50 thousands death annually. because of the severe toxicity and drug resistance, present chemotherapy regimen against diverse forms of leishmania infections is not totally worthwhile. however, sound immunity due to natural infection, implies that vigor cellular immunity against leishmania parasites, via their live, attenuated or killed forms, can be developed in dogs and humans. moreover, genetically conserved antigens (in most of leishmania species), and components of sand fly saliva confer potential immunogenic molecules for leishmania vaccination. vaccines successes in animal studies and some clinical trials clearly justify more researches and investments illuminating opportunities in suitable vaccine designation.